Venetoclax
AML With Mutated NPM1
Kura Oncology, Inc.Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the AML With Mutated NPM1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Shen yang | Phase 3 | B |
Azacitidine Shen yang | Phase 2 | B |
Daunorubicin Shen yang | Phase 2 | B |
Arsenic Trioxide The University of Hong Kong | Phase 2 | CCC |
BN104 Institut de Recherches Internationales Servier (I.R.I.S.) | Phase 1/2 | CC |
View all 14 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →